Terminated PHASE2 INTERVENTIONAL 1-arm NCT01888042

Assessing Everolimus in Fist Line Treatment on Patients With Metastatic Kidney Cancer (POORTOR)

Phase II Study Assessing Everolimus as Fist Line Treatment in Patients With Metastatic Kidney Cancer of Bad Prognosis

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Interventions Everolimus

Updated 5 times since 2017 Last updated: Feb 9, 2016 Started: Jul 31, 2011 Primary completion: Jul 31, 2014 Completion: Jul 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Gustave Roussy, Cancer Campus, Grand Paris

See all terminations from Gustave Roussy, Cancer Campus, Grand Paris

Other Kidney Cancer trials with similar outcome

Browse all Kidney Cancer trials

A PHASE2 clinical study on Kidney Cancer, this trial is terminated or withdrawn. The trial is conducted by Gustave Roussy, Cancer Campus, Grand Paris and has accumulated 5 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Jul 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gustave Roussy, Cancer Campus, Grand Paris

Data source: Gustave Roussy, Cancer Campus, Grand Paris

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Villejuif, France